KR20140045411A - Ｃｘｃｒ４ 길항제의 용도 - Google Patents

Ｃｘｃｒ４ 길항제의 용도 Download PDF

Info

Publication number
KR20140045411A
KR20140045411A KR1020137033309A KR20137033309A KR20140045411A KR 20140045411 A KR20140045411 A KR 20140045411A KR 1020137033309 A KR1020137033309 A KR 1020137033309A KR 20137033309 A KR20137033309 A KR 20137033309A KR 20140045411 A KR20140045411 A KR 20140045411A
Authority
KR
South Korea
Prior art keywords
methylene
bis
phenylenebis
pyridine
teazacyclotetedecane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137033309A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 씨. 데일
게리 제이. 브리저
프랭크 제이. 수
Original Assignee
젠자임 코포레이션
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션, 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 filed Critical 젠자임 코포레이션
Publication of KR20140045411A publication Critical patent/KR20140045411A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020137033309A 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도 Ceased KR20140045411A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486632P 2011-05-16 2011-05-16
US61/486,632 2011-05-16
PCT/US2012/037970 WO2012158707A1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003632A Division KR20200016407A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도

Publications (1)

Publication Number Publication Date
KR20140045411A true KR20140045411A (ko) 2014-04-16

Family

ID=81755014

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207003632A Ceased KR20200016407A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도
KR1020137033309A Ceased KR20140045411A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도
KR1020217023153A Ceased KR20210094672A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207003632A Ceased KR20200016407A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217023153A Ceased KR20210094672A (ko) 2011-05-16 2012-05-15 Ｃｘｃｒ４ 길항제의 용도

Country Status (11)

Country Link
US (2) US20150030561A1 (enExample)
EP (1) EP2709991B1 (enExample)
JP (1) JP2014513727A (enExample)
KR (3) KR20200016407A (enExample)
CN (1) CN103596935A (enExample)
BR (1) BR112013029482A2 (enExample)
ES (1) ES2831049T3 (enExample)
MX (1) MX365242B (enExample)
PL (1) PL2709991T3 (enExample)
RU (1) RU2638802C2 (enExample)
WO (1) WO2012158707A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561012B2 (en) 2013-04-16 2020-02-11 Skyworks Solutions, Inc. Methods related to implementing surface mount devices with ground paths

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611379A2 (pt) 2005-05-02 2010-08-31 Genzyme Corp terapia genética para distúrbios neurometabólicos
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393468B1 (en) * 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3510162A4 (en) * 2016-09-08 2020-02-19 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. GENE THERAPY FOR PATIENTS WITH FANCONI ANEMIA
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
KR20230088917A (ko) * 2020-10-20 2023-06-20 이오엠 파마슈티컬스 인코포레이티드 Covid-19 치료용 eom613
CN113662937B (zh) * 2021-10-09 2022-08-23 江苏省人民医院（南京医科大学第一附属医院） Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途
CN116675708A (zh) * 2023-04-23 2023-09-01 华南师范大学 一类氧化响应的大环化合物、大环配合物及其应用
WO2025122961A1 (en) * 2023-12-08 2025-06-12 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
NZ507161A (en) 1998-03-30 2003-12-19 Northwest Biotherapeutics Inc Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
JP2003516984A (ja) 1999-12-17 2003-05-20 アノーメッド・インコーポレイテッド ケモカインレセプターを結合する複素環式化合物
US20070160574A1 (en) 2000-04-12 2007-07-12 Ahmed Merzouk Design of CXC chemokine analogs for the treatment of human diseases
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2002211393B2 (en) 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
JPWO2002094261A1 (ja) 2001-05-24 2004-09-02 呉羽化学工業株式会社 含窒素化合物からなるｃｘｃｒ４拮抗作用を有する薬剤
PT2371361T (pt) 2001-07-31 2019-09-10 Genzyme Corp Métodos para mobilizar células progenitoras/estaminais
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
WO2004089360A1 (en) 2003-04-02 2004-10-21 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
CN101094684A (zh) 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006095542A1 (ja) 2005-03-04 2006-09-14 Kureha Corporation アミン系化合物を含む医薬組成物
US20080234294A1 (en) * 2005-08-18 2008-09-25 Novartis Ag Cxcr4 Binding Molecules
US20070043012A1 (en) 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
CN101389329A (zh) 2006-02-24 2009-03-18 健赞股份有限公司 增加血流和/或促进组织再生的方法
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
EP2068868A2 (en) 2006-08-02 2009-06-17 Genzyme Corporation Combination therapy
BRPI0715393A2 (pt) 2006-08-07 2013-06-25 Genzyme Corp terapia de combinaÇço
ATE475667T1 (de) 2007-02-28 2010-08-15 Polyphor Ltd Templat-fixierte peptidomimetika
US8363643B2 (en) 2008-06-23 2013-01-29 Research In Motion Limited Method for delivering device and server capabilities
US20110245265A1 (en) 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561012B2 (en) 2013-04-16 2020-02-11 Skyworks Solutions, Inc. Methods related to implementing surface mount devices with ground paths

Also Published As

Publication number Publication date
RU2013155601A (ru) 2015-06-27
ES2831049T3 (es) 2021-06-07
JP2014513727A (ja) 2014-06-05
PL2709991T3 (pl) 2021-04-06
US20150030561A1 (en) 2015-01-29
BR112013029482A2 (pt) 2016-08-09
KR20210094672A (ko) 2021-07-29
US20210161859A1 (en) 2021-06-03
EP2709991A1 (en) 2014-03-26
KR20200016407A (ko) 2020-02-14
MX2013013308A (es) 2014-02-27
RU2638802C2 (ru) 2017-12-15
WO2012158707A1 (en) 2012-11-22
CN103596935A (zh) 2014-02-19
MX365242B (es) 2019-05-28
EP2709991A4 (en) 2014-10-01
EP2709991B1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
KR20140045411A (ko) Ｃｘｃｒ４ 길항제의 용도
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
US20070043012A1 (en) Methods to enhance chemotherapy
US9364459B2 (en) 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
US11628172B2 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
US20110281814A1 (en) Methods and compositions for treating breast cancer
AU2023202746A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
US9018176B2 (en) Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
US20220323423A1 (en) Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
RU2780320C2 (ru) Применение антагонистов cxcr4
JP2021059583A (ja) Ｃｘｃｒ４拮抗薬の使用
KR101554895B1 (ko) 항종양제, 키트 및 암 치료 방법
ES2969766T3 (es) Composiciones terapéuticas para tratar el cáncer de páncreas
CA3020933C (en) Therapeutic compositions for treating pancreatic cancer
WO2020232214A1 (en) Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
JP2020176145A (ja) 血液癌の併用療法
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
MX2008002374A (en) Methods to enhancechemotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170512

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180831

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190719

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190719

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190225

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170512

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20191109

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191017

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190719

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190225

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180831

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170512

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200206